2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic

Program: Oral Abstract Session
Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - R06-R09
Technology and Procedures, Imaging, Omics Technologies, Computational Biology, Gene Editing, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Animal Model
PAPER

211 Genome-scale in vivo CRISPR screenings identify drivers for transformation from preleukemia to leukemia with t(8;21) translocation

Ziyu Niu, Shaowei Qiu, MD2, Tiantian Wang, PhD3, Fang Zhang4, Runxia Gu, MD5, Wenbing Liu6, Yu Liu7, Baowei Ma8, Hanchi Ge9, Haoxin Li10, Xiaoyu Liu11, Qing Rao, MS12, Hui Wei, MD, PhD13, Ying Wang, MD, PhD14, Wenting Zheng15, Min Wang, PhD16, Jun Wei17, Jianxiang Wang Sr, MD, PhD18
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
11 Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China

The t(8;21)(q22;q22) translocation is a common chromosomal abnormality in acute myeloid leukemia (AML). AML1-ETO alone is insufficient to drive leukemogenesis, and no targeted therapies are currently available for this subtype. Although the "two-hit" model has long been proposed, the identity of cooperating genetic lesions that drive the preleukemia-to-leukemia transition remains largely unknown, and the resulting molecular heterogeneity has impeded the development of rational therapeutic strategies. In this study, we tried to address this issue and provided novel insights into leukemia heterogeneity and targeted intervention in t(8;21) AML. 

To systematically identify drivers of myeloid leukemia transition in vivo, we crossbred AML1-ETO;Mx1-Cre (mCherry+) mice (Liu X et. al. Cancer Research 2024) with Cas9LSL (GFP+) mice, generating a preleukemic model that recapitulates the 6heterozygous lesion observed in patients, characterized by excessive accumulation of aberrant hematopoietic stem cells (HSCs). We performed genome-wide in vivo CRISPR/Cas9 loss-of-function screenings in AML1-ETO-expressing c-Kit? HSCs, which were transduced with sgRNA libraries (Ametrine+) and transplanted into lethally irradiated recipients. Among 160 recipients, 53 developed myeloid disease with progressive expansion of triple-positive (mCherry? GFP? Ametrine?) cells in peripheral blood, whereas control mice receiving non-targeting sgRNAs remained disease-free. Deep sequencing of leukemic cells sorted from bone marrow (BM) revealed that a limited number of sgRNAs dominated the read distribution. Ranking sgRNAs by per-sample read fraction and applying a threshold of >15% representation identified 91 candidate drivers, enriched in transcriptional regulation pathways, with the histone methyltransferase complex as a central regulatory network.

Of the 91 candidates, 9 were detected in at least two samples. To assess clinical relevance, we interrogated the mutational landscape of 125 t(8;21) AML patients from cohort of our hospital. Recurrent alterations included the E3 ubiquitin ligase CBL (10%) and the histone methyltransferase EZH2 (6%). In vivo functional validation confirmed that deficiency of either Cbl or Ezh2, in cooperation with AML1-ETO, triggered leukemic transformation and induced overt AML. Loss of Ezh2 or Cbl in AML1-ETO-expressing aberrant HSPCs both enhanced repopulating capacity and drove differentiation toward myeloid lineages.

To delineate leukemic stem cell (LSC) heterogeneity associated with Ezh2 or Cbl deletion, we performed single-cell RNA-seq on c-Kit+ cells. UMAP projection revealed that 4 of the 15 clusters—qHSC, aHSC, LSC-1, and LSC-2—were almost exclusively present in AML1-ETO-expressing samples, whereas AML1-ETO-negative samples were dominated by normal progenitors. Ezh2 deficiency specifically drove expansion of the LSC-1 subset characterized by oxidative phosphorylation pathway activation, whereas Cbl deficiency selectively expanded the LSC-2 subset characterized by Ras/MAPK signaling activation.

We next investigated the clinical impact of gene expression on outcome. Analysis of an independent cohort of 42 t(8;21) patients (Severens JF et. al. Leukemia 2024) confirmed that low EZH2 expression correlates with shorter overall survival. Functionally, serial transplantation demonstrated that both Ezh2 and Cbl deficient leukemias retained robust pathogenicity in vivo, but Ezh2 deficiency conferred higher aggressiveness. Limiting-dilution assays revealed a markedly higher LSC frequency in AML1-ETO;sgEzh2 versus AML1-ETO;sgCbl mice (1:253 versus 1:9461).

Finally, multi-omics integration (CUT & Tag, bulk RNA-seq, and single-cell RNA-seq) identified Pbx1 as a key downstream effector of Ezh2 deficiency. Ezh2 loss led to reduced H3K27me3 repressive marks at the Pbx1 locus, resulting in transcriptional activation of Pbx1. Functional rescue experiments demonstrated that Pbx1 knockout abrogated leukemogenesis driven by Ezh2 loss in cooperation with AML1-ETO. Collectively, our findings establish a functional landscape of cooperating drivers in t(8;21) AML, identify Cbl and Ezh2 as key cooperating lesions, and reveal divergent LSC heterogeneity and clinical outcomes driven by distinct gene deficiency. We further delineate the EZH2–PBX1 axis as a central pathogenetic mechanism. Our study provides a framework for expression-informed prognostic stratification and precision therapy in t(8;21) AML.

Ziyu Niu: No relevant conflicts of interest to declare.